Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.79 |
| ▸ | BCR | P11274 | 19/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16363365 | 1.00 | ABL1 (0.79) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3398043 | 0.88 | ABL1 (0.71) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3397159 | 0.88 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3400145 | 0.88 | ABL1 (0.76) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16363364 | 0.86 | ABL1 (0.80) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL29533256 | 0.86 | ABL1 (0.80) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3400278 | 0.84 | ABL1 (0.80) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3397888 | 0.83 | ABL1 (0.74) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL4666152 | 0.83 | ABL1 (0.74) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL18696176 | 0.82 | ABL1 (0.57) | ABL1BCRKDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | claimed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | claimed |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885KDM4E 863/4885 |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885KDM4E 863/4885 |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ABL1 2/4885BCR 1/4885KDM4E 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.